(2R,3R,4S,5S,6R)-2-[(2R)-4-[(1R,2S,4S,6S,7S,8R,9S,12S,13S,15R,16R,18S)-16-[(2R,3R,4R,5R,6R)-5-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6,15-dihydroxy-7,9,13-trimethyl-5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosan-6-yl]-2-methylbutoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
Internal ID | e43ff85f-e066-43ee-9de4-6a6d4ab80bc2 |
Taxonomy | Lipids and lipid-like molecules > Steroids and steroid derivatives > Steroidal glycosides > Steroidal saponins |
IUPAC Name | (2R,3R,4S,5S,6R)-2-[(2R)-4-[(1R,2S,4S,6S,7S,8R,9S,12S,13S,15R,16R,18S)-16-[(2R,3R,4R,5R,6R)-5-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6,15-dihydroxy-7,9,13-trimethyl-5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosan-6-yl]-2-methylbutoxy]-6-(hydroxymethyl)oxane-3,4,5-triol |
SMILES (Canonical) | CC1C2C(CC3C2(CCC4C3CCC5C4(CC(C(C5)OC6C(C(C(C(O6)CO)OC7C(C(C(C(O7)CO)O)OC8C(C(C(CO8)O)O)O)O)O)O)O)C)C)OC1(CCC(C)COC9C(C(C(C(O9)CO)O)O)O)O |
SMILES (Isomeric) | C[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC[C@@H]5[C@@]4(C[C@H]([C@@H](C5)O[C@H]6[C@@H]([C@H]([C@H]([C@H](O6)CO)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O)O)O)O)O)C)C)O[C@]1(CC[C@@H](C)CO[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O |
InChI | InChI=1S/C50H84O24/c1-19(17-66-44-39(62)36(59)34(57)29(14-51)69-44)7-10-50(65)20(2)32-28(74-50)12-24-22-6-5-21-11-27(25(54)13-49(21,4)23(22)8-9-48(24,32)3)68-46-40(63)37(60)42(31(16-53)71-46)72-47-41(64)43(35(58)30(15-52)70-47)73-45-38(61)33(56)26(55)18-67-45/h19-47,51-65H,5-18H2,1-4H3/t19-,20+,21+,22-,23+,24+,25-,26-,27-,28+,29-,30-,31-,32+,33+,34-,35-,36+,37-,38-,39-,40-,41-,42+,43+,44-,45+,46-,47+,48+,49+,50+/m1/s1 |
InChI Key | RSPUUUSROCUOIJ-ZBGDGXIFSA-N |
Popularity | 0 references in papers |
Molecular Formula | C50H84O24 |
Molecular Weight | 1069.20 g/mol |
Exact Mass | 1068.53525354 g/mol |
Topological Polar Surface Area (TPSA) | 387.00 Ų |
XlogP | -2.30 |
Atomic LogP (AlogP) | -4.35 |
H-Bond Acceptor | 24 |
H-Bond Donor | 15 |
Rotatable Bonds | 15 |
There are no found synonyms. |
![2D Structure of (2R,3R,4S,5S,6R)-2-[(2R)-4-[(1R,2S,4S,6S,7S,8R,9S,12S,13S,15R,16R,18S)-16-[(2R,3R,4R,5R,6R)-5-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6,15-dihydroxy-7,9,13-trimethyl-5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosan-6-yl]-2-methylbutoxy]-6-(hydroxymethyl)oxane-3,4,5-triol 2D Structure of (2R,3R,4S,5S,6R)-2-[(2R)-4-[(1R,2S,4S,6S,7S,8R,9S,12S,13S,15R,16R,18S)-16-[(2R,3R,4R,5R,6R)-5-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6,15-dihydroxy-7,9,13-trimethyl-5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosan-6-yl]-2-methylbutoxy]-6-(hydroxymethyl)oxane-3,4,5-triol](https://plantaedb.com/storage/docs/compounds/2023/11/76249bf0-8724-11ee-985a-c300bf51ed5c.jpg)
Target | Value | Probability (raw) | Probability (%) |
---|---|---|---|
Human Intestinal Absorption | - | 0.5246 | 52.46% |
Caco-2 | - | 0.8807 | 88.07% |
Blood Brain Barrier | - | 0.6750 | 67.50% |
Human oral bioavailability | - | 0.8429 | 84.29% |
Subcellular localzation | Mitochondria | 0.6174 | 61.74% |
OATP2B1 inhibitior | - | 1.0000 | 100.00% |
OATP1B1 inhibitior | + | 0.8695 | 86.95% |
OATP1B3 inhibitior | + | 0.9480 | 94.80% |
MATE1 inhibitior | - | 0.9612 | 96.12% |
OCT2 inhibitior | + | 0.6250 | 62.50% |
BSEP inhibitior | + | 0.8126 | 81.26% |
P-glycoprotein inhibitior | + | 0.7424 | 74.24% |
P-glycoprotein substrate | + | 0.6017 | 60.17% |
CYP3A4 substrate | + | 0.7557 | 75.57% |
CYP2C9 substrate | - | 0.8016 | 80.16% |
CYP2D6 substrate | - | 0.8288 | 82.88% |
CYP3A4 inhibition | - | 0.9473 | 94.73% |
CYP2C9 inhibition | - | 0.9215 | 92.15% |
CYP2C19 inhibition | - | 0.8997 | 89.97% |
CYP2D6 inhibition | - | 0.9561 | 95.61% |
CYP1A2 inhibition | - | 0.9215 | 92.15% |
CYP2C8 inhibition | + | 0.6949 | 69.49% |
CYP inhibitory promiscuity | - | 0.9616 | 96.16% |
UGT catelyzed | - | 0.5000 | 50.00% |
Carcinogenicity (binary) | - | 0.9800 | 98.00% |
Carcinogenicity (trinary) | Non-required | 0.6223 | 62.23% |
Eye corrosion | - | 0.9917 | 99.17% |
Eye irritation | - | 0.9039 | 90.39% |
Skin irritation | - | 0.6555 | 65.55% |
Skin corrosion | - | 0.9521 | 95.21% |
Ames mutagenesis | - | 0.7378 | 73.78% |
Human Ether-a-go-go-Related Gene inhibition | + | 0.7716 | 77.16% |
Micronuclear | - | 0.9100 | 91.00% |
Hepatotoxicity | - | 0.8783 | 87.83% |
skin sensitisation | - | 0.9420 | 94.20% |
Respiratory toxicity | + | 0.6778 | 67.78% |
Reproductive toxicity | + | 0.7000 | 70.00% |
Mitochondrial toxicity | - | 0.5375 | 53.75% |
Nephrotoxicity | - | 0.9561 | 95.61% |
Acute Oral Toxicity (c) | I | 0.8185 | 81.85% |
Estrogen receptor binding | + | 0.8484 | 84.84% |
Androgen receptor binding | + | 0.6785 | 67.85% |
Thyroid receptor binding | - | 0.5210 | 52.10% |
Glucocorticoid receptor binding | + | 0.6288 | 62.88% |
Aromatase binding | + | 0.6912 | 69.12% |
PPAR gamma | + | 0.7740 | 77.40% |
Honey bee toxicity | - | 0.5693 | 56.93% |
Biodegradation | - | 0.7750 | 77.50% |
Crustacea aquatic toxicity | - | 0.6100 | 61.00% |
Fish aquatic toxicity | + | 0.7523 | 75.23% |
Proven Targets:
CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
---|---|---|---|---|---|
No proven targets yet! |
Predicted Targets (via Super-PRED):
CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
---|---|---|---|---|
CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 98.30% | 91.11% |
CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 98.30% | 96.09% |
CHEMBL218 | P21554 | Cannabinoid CB1 receptor | 97.47% | 96.61% |
CHEMBL226 | P30542 | Adenosine A1 receptor | 95.96% | 95.93% |
CHEMBL204 | P00734 | Thrombin | 95.86% | 96.01% |
CHEMBL2955 | O95136 | Sphingosine 1-phosphate receptor Edg-5 | 95.80% | 92.86% |
CHEMBL3137262 | O60341 | LSD1/CoREST complex | 93.81% | 97.09% |
CHEMBL4302 | P08183 | P-glycoprotein 1 | 93.50% | 92.98% |
CHEMBL3892 | Q99500 | Sphingosine 1-phosphate receptor Edg-3 | 93.29% | 97.29% |
CHEMBL3880 | P07900 | Heat shock protein HSP 90-alpha | 92.99% | 96.21% |
CHEMBL4581 | P52732 | Kinesin-like protein 1 | 92.63% | 93.18% |
CHEMBL1994 | P08235 | Mineralocorticoid receptor | 91.70% | 100.00% |
CHEMBL253 | P34972 | Cannabinoid CB2 receptor | 91.47% | 97.25% |
CHEMBL233 | P35372 | Mu opioid receptor | 90.99% | 97.93% |
CHEMBL4203 | Q9HAZ1 | Dual specificity protein kinase CLK4 | 90.13% | 94.45% |
CHEMBL2534 | O15530 | 3-phosphoinositide dependent protein kinase-1 | 89.91% | 95.36% |
CHEMBL221 | P23219 | Cyclooxygenase-1 | 89.44% | 90.17% |
CHEMBL237 | P41145 | Kappa opioid receptor | 89.26% | 98.10% |
CHEMBL4618 | P09960 | Leukotriene A4 hydrolase | 89.10% | 97.86% |
CHEMBL2094135 | Q96BI3 | Gamma-secretase | 88.22% | 98.05% |
CHEMBL2842 | P42345 | Serine/threonine-protein kinase mTOR | 87.94% | 92.78% |
CHEMBL4187 | Q99250 | Sodium channel protein type II alpha subunit | 87.47% | 95.50% |
CHEMBL6136 | O60341 | Lysine-specific histone demethylase 1 | 86.91% | 95.58% |
CHEMBL220 | P22303 | Acetylcholinesterase | 86.87% | 94.45% |
CHEMBL1907603 | Q05586 | Glutamate NMDA receptor; GRIN1/GRIN2B | 86.74% | 95.89% |
CHEMBL2360 | P00492 | Hypoxanthine-guanine phosphoribosyltransferase | 85.97% | 87.38% |
CHEMBL5469 | Q14289 | Protein tyrosine kinase 2 beta | 85.83% | 91.03% |
CHEMBL206 | P03372 | Estrogen receptor alpha | 85.19% | 97.64% |
CHEMBL2996 | Q05655 | Protein kinase C delta | 84.37% | 97.79% |
CHEMBL5608 | Q16288 | NT-3 growth factor receptor | 84.26% | 95.89% |
CHEMBL4303 | P08238 | Heat shock protein HSP 90-beta | 84.22% | 96.77% |
CHEMBL1907605 | P24864 | Cyclin-dependent kinase 2/cyclin E1 | 84.15% | 92.88% |
CHEMBL3359 | P21462 | Formyl peptide receptor 1 | 83.84% | 93.56% |
CHEMBL4681 | P42330 | Aldo-keto-reductase family 1 member C3 | 83.81% | 89.05% |
CHEMBL3130 | O00329 | PI3-kinase p110-delta subunit | 83.78% | 96.47% |
CHEMBL335 | P18031 | Protein-tyrosine phosphatase 1B | 83.71% | 95.17% |
CHEMBL4478 | Q00975 | Voltage-gated N-type calcium channel alpha-1B subunit | 83.59% | 97.14% |
CHEMBL2274 | Q9H228 | Sphingosine 1-phosphate receptor Edg-8 | 83.56% | 100.00% |
CHEMBL1293249 | Q13887 | Kruppel-like factor 5 | 83.27% | 86.33% |
CHEMBL4685 | P14902 | Indoleamine 2,3-dioxygenase | 83.10% | 96.38% |
CHEMBL5255 | O00206 | Toll-like receptor 4 | 82.55% | 92.50% |
CHEMBL5888 | Q99558 | Mitogen-activated protein kinase kinase kinase 14 | 82.54% | 100.00% |
CHEMBL2095194 | P08709 | Coagulation factor VII/tissue factor | 82.14% | 99.17% |
CHEMBL3713062 | P10646 | Tissue factor pathway inhibitor | 81.49% | 97.33% |
CHEMBL2072 | P35499 | Sodium channel protein type IV alpha subunit | 81.47% | 92.32% |
CHEMBL5524 | Q99873 | Protein-arginine N-methyltransferase 1 | 81.42% | 96.67% |
CHEMBL1871 | P10275 | Androgen Receptor | 81.26% | 96.43% |
CHEMBL2730 | P21980 | Protein-glutamine gamma-glutamyltransferase | 80.39% | 92.38% |
Below are displayed all the plants proven (via scientific papers) to contain this
compound!
To see more specific details click the taxa you are interested in.
To see more specific details click the taxa you are interested in.
Allium stipitatum |
PubChem | 162944979 |
LOTUS | LTS0118907 |
wikiData | Q105244814 |